At a glance
This program funds product-driven therapeutic and diagnostic research on Lyme disease and other tick-borne diseases and conditions, with the goal of improving patient care and quality of life. Eligible applicants include extramural and intramural U.S. Department of War organizations, as well as foreign and domestic for-profit, nonprofit, public, and private organizations; awards are made to eligible organizations, not individuals. The program expects to fund about two awards, with a total cost cap of $1.325 million per award and a maximum project period of 3 years. Cost sharing is not required, and applications must focus on Lyme disease and/or other tick-borne diseases, with emphasis on persistent Lyme disease and other U.S.-endemic tick-borne diseases; clinical trials are not allowed.
What it funds
Official description from grants.gov
Summary: The intent of the fiscal year 2026 (FY26) Tick-Borne Disease Research Program (TBDRP) Therapeutic/Diagnostic Research Award (TDRA) is to support product-driven therapeutic and diagnostic development research aimed at reducing the burden of Lyme disease and/or other tick-borne diseases and conditions, and improving patient care and/or quality of life. Treatment-focused applications should be therapeutic evaluation studies designed to advance new ideas aimed at drug or treatment discovery that are still in the early/preclinical stages of development. Diagnosis-focused applications should propose diagnostic approaches that will be readily integrated into clinical settings. https://cdmrp.health.mil/pubs/press/2026/tbdrppreann
Who can apply
- Unrestricted